北陆药业(300016) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was approximately ¥843.90 million, representing a 2.00% increase compared to ¥827.34 million in 2020[19]. - The net profit attributable to shareholders decreased by 28.46% to approximately ¥124.99 million from ¥174.70 million in 2020[19]. - The net profit after deducting non-recurring gains and losses was approximately ¥93.52 million, down 38.36% from ¥151.73 million in 2020[19]. - The net cash flow from operating activities was approximately ¥108.73 million, a decrease of 38.22% compared to ¥176.00 million in 2020[19]. - Basic earnings per share fell by 30.56% to ¥0.25 from ¥0.36 in 2020[19]. - The total assets at the end of 2021 were approximately ¥2.90 billion, an increase of 1.94% from ¥2.85 billion at the end of 2020[19]. - The net assets attributable to shareholders increased by 6.58% to approximately ¥1.86 billion from ¥1.74 billion at the end of 2020[19]. - The weighted average return on net assets decreased to 7.00% from 11.49% in 2020, a decline of 4.49 percentage points[19]. Revenue Breakdown - In Q1 2021, the company reported revenue of approximately ¥222.08 million, with a net profit attributable to shareholders of about ¥50.45 million[21]. - The company's revenue in Q2 2021 increased to approximately ¥313.20 million, with net profit rising to about ¥66.02 million[21]. - In Q3 2021, revenue dropped to approximately ¥145.56 million, and net profit fell to ¥13.26 million, indicating a significant decline[21]. - The company’s contrast agent products generated sales revenue of approximately ¥635.69 million in 2021, remaining stable compared to the previous year[32]. - The iodine contrast agent injection product achieved sales revenue of approximately ¥32.99 million in Q4 2021, reflecting a year-on-year increase of 19.69%[32]. - The sales revenue of Jiwei Zhenxin Granules reached 141.40 million yuan, an increase of 26.96% year-on-year[38]. - The sales revenue of the company's hypoglycemic products, including Glimepiride and Repaglinide, declined to 48.88 million yuan, a decrease of 31.11% year-on-year[39]. - Haichang Pharmaceutical achieved a sales revenue of 124.44 million yuan, a significant increase of 1798.27% year-on-year, marking a historical high for the company[41]. Investment and Expansion Plans - The company plans to invest 192 million yuan to enhance its production capabilities in gadolinium and iodine contrast agents, aiming to improve cost and competitive advantages[43]. - The company plans to diversify its contrast agent product line with the anticipated launch of gadobutrol injection within the year[34]. - The company is actively expanding its overseas market, achieving sales of contrast agents in 6 countries, with 5 countries completing registration[58]. - The company plans to deepen its focus on the contrast agent and raw material drug sectors, aiming to enhance domestic market share and sales growth[112]. - The company intends to increase R&D investment, targeting at least three new product projects each year through various development strategies[112]. - The company aims to accelerate overseas registration and market expansion to boost international sales[113]. - The company will actively pursue international market expansion for its contrast agents and raw materials, with a focus on obtaining EU compliance certification for its production facilities[125]. Research and Development - The company is focusing on the development of multiple central nervous system products, which are expected to synergize with Jiwei Zhenxin Granules to enhance brand influence[45]. - The number of R&D personnel increased by 23.36% to 132 in 2021, with a higher proportion of personnel holding bachelor's degrees[82]. - R&D investment amounted to ¥51,593,248.72 in 2021, accounting for 6.11% of operating revenue, down from 7.25% in 2020[82]. - The company will establish a comprehensive risk management and control system for its R&D projects to address potential risks in drug development[116]. Corporate Governance - The company maintained compliance with corporate governance standards, aligning with the requirements of the Shenzhen Stock Exchange and relevant laws[132]. - The company has established a complete independent operational capability, ensuring independence from its controlling shareholders in various aspects[132]. - The company’s board of directors and supervisory board operate independently, fulfilling their respective roles[132]. - The company has a diverse board composition, including independent directors with expertise in academia and industry, which supports robust decision-making processes[143][144]. - The company has implemented a stock buyback program, which has resulted in a significant reduction in outstanding shares, thereby potentially increasing shareholder value[139]. Employee and Management - The total number of employees at the end of the reporting period was 905, with 331 in production, 267 in sales, and 185 in technical roles[161]. - The company has established a scientific and reasonable salary management system to improve performance and organizational efficiency[162]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.1364 million[149]. - The company has a performance management system in place for determining the remuneration of senior management[147]. Risk Management - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding potential risks[5]. - The company will enhance its internal control management to effectively control operational risks as a key focus for 2022[129]. - The internal control system was enhanced to address operational, financial, and legal risks, ensuring effective management and compliance with regulations[175]. Social Responsibility - A total of 2 million yuan was allocated for poverty alleviation efforts in the Miyun District, with 400,000 yuan distributed in the reporting period[185]. - The company committed to distributing at least 10% of the distributable profits in cash annually from 2020 to 2022, with compliance confirmed[188].